Citations

Clear

1727 citation(s) found for "Fu, Alan".

A Decision Analysis of Observation vs Immediate Reintervention for Asymptomatic Residual Fragments Less than 4 mm Following Ureteroscopic Lithotripsy
Ursiny, Michal, Yaghoubian, Alan J., Humphreys, Mitchell R. , Brotherhood, Hilary, Chew, Benjamin, Monga, Manoj, Krambeck, Amy E. , Charchenko, Cameron, Wang, An Qi, Sur, Roger L. , Miller, Nicole L. , Marien, Tracy , Chang, Yui-Hui H., Knudsen, Bodo E. , Lange, Dirk , Yong, Courtney , Matlaga, Brian R., Shah, Ojas , Pais, Vernon M., Lipkin, Michael E. , Eisner, Brian H. , Miller, Nicole L

Mayo Clinic

Urology Practice | February 4, 2019 | Volume: 6 | Issue: 5 | Pages: 294-299

10.1097/upj.0000000000000038 | PMID 37317352 Get It

Abstract WP403: Factors Associated With Patient-Reported Shared Decision-Making for Stroke Prevention in Atrial Fibrillation
O’Brien, Emily C. , Pieper, Karen S. , Thiem, Rebecca, Kowey, Peter R. , Ezekowitz, Michael D. , Go, Alan S. , Singer, Daniel E. , Reiffel, James A. , Piccini, Jonathan P. , Fonarow, Gregg C. , Chan, Paul S. , Freeman, James V. , Naccarelli, Gerald V. , Mahaffey, Kenneth W. , Gersh, Bernard J.

Mayo Clinic

Stroke | January 30, 2019 | Volume: 50 | Issue: Suppl_1 | Pages: No page available

10.1161/str.50.suppl_1.wp403 Get It

Introduction: Shared decision making (SDM) incorporates patient and physician values and preferences into treatment selection. While multiple therapeutic options are available for stroke prevention in atrial fibrillation (AF), few studies have examined factors associated with SDM regarding choice of antithrombotic strategy. Methods: We evaluated survey data from 1006 patients with new-onset AF enrolled at 56 sites participating in a substudy of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT II), an outpatient AF registry in the US. Patients were asked: “When choosing your blood thinner(s), who made this treatment decision?”, and SDM was defined as a response of “equally me and my healthcare provider (HCP)”, “mostly me” or “entirely me”, while no SDM was defined as a response of “mostly my HCP” or “entirely my HCP”. Multivariable logistic regression models evaluated associations between 13 patient-level factors, self-reported understanding of treatment options, and SDM for antithrombotic therapy. Results: Most patients allowed their HCP to make the therapeutic decisions on antithrombotic strategy, with 246 (24.5%) reporting SDM. Patients reporting SDM were more often female (47.2% vs. 40.5%) and were more frequently insured by Medicare (40.2% vs. 34.5%) than patients reporting no SDM. Among patients taking warfarin, median time in therapeutic range was higher among patients reporting SDM than among those not reporting SDM. In multivariable models, chronic obstructive pulmonary disease was associated with lower odds of SDM while self-reported understanding of blood thinner options was associated with higher odds of SDM (Table). Conclusion: One in four patients in an outpatient AF registry reported that their current antithrombotic strategy was the result of a shared decision making process. Additional work is need to determine whether patient-reported SDM is associated with medication adherence and outcomes of therapy.
TBX3 promotes progression of pre‐invasive breast cancer cells by inducing EMT and directly up‐regulating SLUG
Krstic, Milica , Kolendowski, Bart , Cecchini, Matthew J. , Postenka, Carl O., Hassan, Haider M., Andrews, Joseph, MacMillan, Connor D., Williams, Karla C. , Torchia, Joseph , Tuck, Alan B., Leong, Hon S. , Brackstone, Muriel , Chambers, Ann F.

Mayo Clinic

The Journal of Pathology | January 30, 2019 | Volume: 248 | Issue: 2 | Pages: 191-203

10.1002/path.5245 | PMID 30697731 Get It

AbstractThe acquisition of cellular invasiveness by breast epithelial cells and subsequent transition from ductal carcinoma in situ (DCIS) to invasive breast cancer is a critical step in breast cancer progression. Little is known about the molecular dynamics governing this transition. We have previously shown that overexpression of the transcriptional regulator TBX3 in DCIS‐like cells increases survival, growth, and invasiveness. To explore this mechanism further and assess direct transcriptional targets of TBX3 in a high‐resolution, isoform‐specific context, we conducted genome‐wide chromatin‐immunoprecipitation (ChIP) arrays coupled with transcriptomic analysis. We show that TBX3 regulates several epithelial–mesenchymal transition (EMT)‐related genes, including SLUG and TWIST1. Importantly, we demonstrate that TBX3 is a direct regulator of SLUG expression, and SLUG expression is required for TBX3‐induced migration and invasion. Assessing TBX3 by immunohistochemistry in early‐stage (stage 0 and stage I) breast cancers revealed high expression in low‐grade lesions. Within a second independent early‐stage non‐high‐grade cohort, we observed an association between TBX3 level in the DCIS and size of the invasive focus. Additionally, there was a positive correlation between TBX3 and SLUG, and TBX3 and TWIST1 in the invasive carcinoma. Pathway analysis revealed altered expression of several proteases and their inhibitors, consistent with the ability to degrade basement membrane in vivo. These findings strongly suggest the involvement of TBX3 in the promotion of invasiveness and progression of early‐stage pre‐invasive breast cancer to invasive carcinoma through the low‐grade molecular pathway. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).
Hatch, Ace J. , Starr, Mark D. , Brady, John C. , Innocenti, Federico , Lenz, Heinz‐Josef , Hurwitz, Herbert I. , Ou, Fang‐Shu , Zemla, Tyler , Liu, Yingmiao , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M. , Venook, Alan P. , Nixon, Andrew B.

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 588-588

10.1200/jco.2019.37.4_suppl.588 Get It

588 Background: CALGB/SWOG 80405 found no difference in overall survival (OS) or progression-free survival (PFS) in 1137 patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with either the anti-VEGF agent bevacizumab (Bev) or the anti-EGFR agent cetuximab (Cet) in combination with chemotherapy (FOLFOX or FOLFIRI) as first-line therapy. Additional molecular biomarkers are required for the optimization of treatment choices for patients with mCRC. Methods: Levels of 24 proteins were assayed in EDTA-plasma samples using multiplex ELISA techniques. Plasma samples were collected at baseline and cycle 2 day 1 (C2D1). Analyses of baseline markers have been presented previously. Changes from baseline to C2D1 were expressed as an L-ratio (LR, log2 of C2D1 divided by baseline measure). LRs dichotomized at 0 were analyzed for potential prognostic and predictive effects on OS and PFS using Cox models while adjusting for confounders (post-hoc optimized cutpoints were used for PLGF, TIMP1, VCAM1, and VEGFR3 due to skew in the distributions of these markers). P-values are not corrected for multiple testing. Results: Baseline and matched C2D1 samples from 446 patients (212 Bev/234 Cet) were available for analysis. Thirteen markers were differentially modulated between arms (p < 0.05). Early increases in CD73 (p = 0.001), ICAM1 (p = 0.022), TIMP1 (p = 0.001), TSP2 (p = 0.024), and VEGFR3 (p = 0.006) were prognostic for shorter OS. Increases in ICAM1 (p = 0.008), TIMP1 (p = 0.042), and TGFB1 (p = 0.039) were prognostic for shorter PFS. Changes in VEGFR3 (pint = 0.097) and TGFBR3 (pint = 0.052) were predictive for OS and PFS, respectively. No other markers were predictive for OS or PFS (p < 0.1). Conclusions: Changes in circulating plasma protein biomarkers observed in patients enrolled in CALGB/SWOG 80405 were both prognostic and predictive for OS and PFS and warrant further study. Such changes could provide valuable information and help guide treatment decisions. Support: U10CA180821, U10CA180882, U10CA180888, U10CA180830; ClinicalTrials.gov: NCT00265850. [Table: see text]
Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance)
Weiser, Martin R. , Mamon, Harvey J. , Gollub, Marc J. , Basch, Ethan , Shi, Qian , Shi, Qian , Gollub, Marc , Schrag, Deborah , Saltz, Leonard B. , Basch, Ethan , Venook, Alan P.

Mayo Clinic

Clinical Trials | January 28, 2019 | Volume: 16 | Issue: 2 | Pages: 165-175

10.1177/1740774518824539 | PMID 30688523 Get It

Background More than half of the 40,000 incident rectal cancer patients in the United States each year are diagnosed at clinical stage II and III (locally advanced stage). For this group, high rates of cure can be achieved with the combination of pelvic radiation and sensitizing 5-fluorouracil (chemoradiation), surgery and chemotherapy, but treatment is long, arduous and toxicities are substantial. The PROSPECT trial (N1048, NCT01515787) was designed to determine whether neoadjuvant chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX) could be used as an alternative to neoadjuvant chemoradiation without compromising treatment outcomes and to spare these patients excess toxicity. The statistical design balanced the twin co-primary goals of achieving low local and distant recurrence rates. Study design features contended with the need for stringent safeguards given limited phase II data, the need for straightforward criteria to facilitate both accrual and protocol fidelity and the importance of patients’ perspectives on symptom burden and treatment toxicity. Methods PROSPECT is an ongoing multi-site two-group seamless phase II/III randomized trial comparing standard neoadjuvant chemoradiation versus neoadjuvant chemotherapy with selective use of chemoradiation for patients with locally advanced rectal cancer. Challenges addressed in the design and conduct of PROSPECT have included the following: (1) setting safety thresholds given limited single-center phase II data, (2) establishing workable eligibility criteria, (3) balancing competing time to local and distant recurrence as co-primary endpoints and (4) obtaining reliable and complete data for patients’ symptom burden. The design and implementation challenges, choices, modifications and their implications for the design of future national cooperative group clinical trials are presented. Results PROSPECT incorporated stringent thresholds for both complete surgical resection (R0) and the time to local recurrence as early stopping rules. When predetermined stopping criteria were not met after evaluation of the first 366 participants in the randomized phase II, the study transitioned seamlessly to phase III with cumulative accrual of over 1000 participants. Eligibility criteria stipulating rectal tumor location based on distance from the anal verge were unworkable, and the protocol was amended to a more pragmatic approach that assigned surgeons with primary responsibility for determining eligibility. Central radiology review was feasible and in some cases prompted discontinuation of protocol treatment. Participation in toxicity reporting using the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events was uniformly high and was well accepted by participants from over 200 sites in the United States, Canada and Switzerland. Conclusion The strategies used to overcome these obstacles may inform the design of other studies that involve multi-modality treatment interventions, particularly trials where implementation of consistent criteria for eligibility and outcomes across hundreds of practice settings is necessary.
Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome
Saito, Yuri A. , Almazar, Ann E., Tilkes, Katherine E., Choung, Rok Seon , Norstrand, Michael D. Van, Schleck, Cathy D. , Zinsmeister, Alan R., Talley, Nicholas J. , Van Norstrand, Michael D, Choung, Rok Seon

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 20, 2019 | Volume: 49 | Issue: 4 | Pages: 389-397

10.1111/apt.15077 | PMID 30663077 Get It

Summary Background Pregabalin is a calcium channel α2δ ligand that modifies visceral hypersensitivity in IBS patients. Clinical data for pregabalin in IBS are lacking. Aim To test the efficacy of pregabalin on gastrointestinal symptoms in IBS patients. Methods A double‐blind, placebo‐controlled trial was performed. Adults meeting IBS Rome III criteria with ≥3 pain attacks per month were randomised to pregabalin 225 mg vs placebo twice daily for 12 weeks. Questionnaires were completed weekly. The primary endpoint was average pain Bowel Symptom Scale (BSS) scores weeks 9‐12. An intention‐to‐treat analysis of covariance evaluated treatment effects on quantitative endpoints, adjusting for age and gender. Adequate relief and change in pain score were assessed using a chi‐squared test. Results Eighty‐five patients were recruited and randomised. Sample characteristics include: mean age 39.4 (SD = 14.6); 73 (86%) female; 37 (44%) IBS‐D, 29 (35%) IBS‐M, 18 (21%) IBS‐C. The pregabalin arm had lower average pain‐BSS scores weeks 9‐12 (25 vs 42, P = 0.008). Compared with placebo, the overall IBS BSS severity score was lower in the pregabalin arm (26 vs 42, P = 0.009). Differences were observed for the diarrhoea‐BSS and bloating‐BSS scores ( P = 0.049 and 0.016, respectively). No differences between groups were seen for constipation‐BSS scores. Adequate relief was not different between the two arms (46% vs 36%, P = 0.35). 63% pregabalin vs 45% placebo had a change in pain score ≥30 at week 12 from baseline ( P = 0.10). Post‐treatment IBS‐QoL scores did not differ between groups. Conclusion This trial suggests that pregabalin may be beneficial for IBS abdominal pain, bloating and diarrhoea.
Predictive utility of an adapted Marshall head CT classification scheme after traumatic brain injury
Pretz, Christopher R. , Bell, Kathleen , Arciniegas, David B. , Bodien, Yelena G. , Hart, Tessa , Johnson‐Greene, Douglas, Kowalski, Robert G. , Weintraub, Alan, Zafonte, Ross , Brown, Allen W. , Bell, Kathleen , Hammond, Flora M. , Dams-O’Connor, Kristen , Giacino, Joseph T. , Johnson‐Greene, Doug , Walker, William C.

Mayo Clinic

Brain Injury | January 19, 2019 | Volume: 33 | Issue: 5 | Pages: 610-617

10.1080/02699052.2019.1566970 | PMID 30663426 Get It

Asthma in the older adult
Nanda, Anil , Baptist, Alan P. , Divekar, Rohit , Parikh, N., Seggev, Joram S., Yusin, Joseph, Nyenhuis, Sharmilee Maria

Mayo Clinic

Journal of Asthma | January 18, 2019 | Volume: 57 | Issue: 3 | Pages: 241-252

10.1080/02770903.2019.1565828 | PMID 30656998 Get It

Relationship between Selective Serotonin Reuptake Inhibitors and Risk of Dental Implant Failure
Gonzalez, Ricardo L. Vidal, Lohse, Christine M. , Carr, Alan B. , Jia, Li

Mayo Clinic

Journal of Prosthodontics | January 14, 2019 | Volume: 28 | Issue: 3 | Pages: 252-257

10.1111/jopr.13015 | PMID 30637850 Get It

AbstractPurposeTo identify associations between implant failure and selective serotonin reuptake inhibitor (SSRI) medication use in a cohort of consecutive patients receiving dental implants during a 20‐year period.Materials and MethodsA retrospective review was conducted of all patients who received at least 1 dental implant from January 1, 1995, through December 31, 2014, assessing their history of SSRI use, active SSRI use, and SSRI use during follow‐up with implant failure. Cox proportional hazards regression models assessed associations between demographic characteristics and SSRI use with implant failure, and outcomes were summarized with hazard ratios (HRs) and 95% confidence intervals (CIs). Follow‐up SSRI use was analyzed with time‐dependent covariates.ResultsDuring the study period, 5456 patients received their first implant (median age, 53 years). The median duration of follow‐up was 5.3 years (interquartile range, 2.3‐10.2 years) for the 4927 patients who did not have implant failure. For the 529 patients who had implant failure, it occurred at a median of 0.5 years. After adjusting for age, sex, and era of implant, history of use of the SSRI sertraline was associated with an increased risk of implant failure among all patients (hazard ratio [HR], 1.60; 95% CI, 1.15‐2.23; p = 0.006) and among the subset of patients with a history of SSRI use (HR, 1.64; 95% CI, 1.07‐2.52; p = 0.02).ConclusionsIn the population reviewed, a history of sertraline use was associated with a 60% greater risk of implant failure; however, active SSRI use at the time of implant placement or during follow‐up was not significantly associated with an increased risk of implant failure.
Response to Weisschuh’s “Comment: a novel missense mutation in BEST1 associated with an autosomal-dominant vitreoretinochoroidopathy (ADVIRC) phenotype”
Mano, Fukutaro , Pfannkoch, Cynthia, Olsen, Timothy W. , Marmorstein, Alan D. , Pulido, José S. , LoBue, Stephen A , Marmorstein, Alan D

Mayo Clinic

Ophthalmic Genetics | January 11, 2019 | Volume: 40 | Issue: 1 | Pages: 88-89

10.1080/13816810.2018.1558264 | PMID 30632873 Get It